Symbols / ASBP $0.85 -12.89%
ASBP Chart
About
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.27M |
| Enterprise Value | 9.30M | Income | -20.54M | Sales | 1.94K |
| Book/sh | -9.26 | Cash/sh | 0.72 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 2198.09 | P/B | -0.09 | P/C | — |
| EV/EBITDA | — | EV/Sales | 4789.26 | Quick Ratio | 0.14 |
| Current Ratio | 0.17 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -25.66 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -195.11% |
| ROE | — | ROIC | — | Gross Margin | 45.54% |
| Oper. Margin | -590.16% | Profit Margin | 0.00% | Shs Outstand | 5.02M |
| Shs Float | 2.33M | Short Float | 8.48% | Short Ratio | 0.34 |
| Short Interest | — | 52W High | 35.00 | 52W Low | 0.76 |
| Beta | 0.89 | Avg Volume | 998.68K | Volume | 305.53K |
| Target Price | — | Recom | None | Prev Close | $0.97 |
| Price | $0.85 | Change | -12.89% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.85
Latest analyst target
3. DCF / Fair value
$60.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.85
Low
—
High
—
Mean
—
- Sprinkle-under-tongue caffeine sticks arrive at major 2026 fitness show - Stock Titan hu, 12 Mar 2026 12
- ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin – Retail Expects Licensing Negotiations Soon - Stocktwits Wed, 07 Jan 2026 08
- ASBP - Aspire Biopharma Holdings Inc Latest Stock News & Market Updates - Stock Titan ue, 27 Jan 2026 19
- Dry caffeine powder hits c-stores: inside BUZZ BOMB's new 6-pack - Stock Titan ue, 10 Mar 2026 12
- ASBP SEC Filings - Aspire Biopharma Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan Wed, 04 Mar 2026 11
- Tiny drug developer shrinks share count 40-to-1 to keep Nasdaq listing - Stock Titan Wed, 14 Jan 2026 08
- Ashley Paulson’s 100-mile world record drives 400K Buzz Bomb views - Stock Titan Wed, 25 Feb 2026 08
- Two million under-tongue caffeine packs anchor Aspire's BUZZ BOMB relaunch - Stock Titan hu, 22 Jan 2026 08
- FDA backs trial of faster-acting aspirin powder for heart attacks - Stock Titan Wed, 07 Jan 2026 08
- Sublingual aspirin powder targets emergency heart attack treatment - Stock Titan hu, 29 Jan 2026 08
- BUZZ BOMB caffeine gets sleek new look and direct-to-consumer website - Stock Titan Wed, 21 Jan 2026 08
- Buzz Bomb's dry caffeine sticks get PR boost from ChicExecs - Stock Titan hu, 19 Feb 2026 08
- Aspire Biopharma (Nasdaq: ASBP) targets H1 2026 NDA after fast-acting aspirin data - Stock Titan hu, 04 Dec 2025 08
- New under-the-tongue Xanax powder aims to calm panic attacks in minutes - Stock Titan ue, 20 Jan 2026 08
- Aspire Biopharma (Nasdaq: ASBP) gains extension, moves to Nasdaq Capital Market - Stock Titan Fri, 12 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 20000 | 7800 | — | Purchase at price 0.39 per share. | FELL DONALD G. | Director | — | 2025-06-05 00:00:00 | D |
| 1 | 20000 | 7800 | — | Purchase at price 0.39 per share. | FELL DONALD G. | Director | — | 2025-06-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.21 |
| NormalizedEBITDA | -11.65M | 4.47M | -596.49K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.54M | 4.46M | -597.12K |
| ReconciledDepreciation | 0.00 | 0.00 | 0.00 |
| ReconciledCostOfRevenue | 0.00 | 0.00 | |
| EBITDA | -11.65M | 4.47M | -596.49K |
| EBIT | -11.65M | 4.47M | -596.49K |
| NetInterestIncome | -342.95K | 5.80M | 0.00 |
| InterestExpense | 891.62K | 8.97K | 0.00 |
| InterestIncome | 548.68K | 5.81M | |
| NormalizedIncome | -12.54M | 4.46M | -597.12K |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.54M | 4.46M | -597.12K |
| TotalExpenses | 3.09M | 1.34M | 596.49K |
| DilutedAverageShares | 1.15M | 1.15M | 1.15M |
| BasicAverageShares | 1.15M | 1.15M | 1.15M |
| DilutedEPS | -10.90 | 3.88 | -0.52 |
| BasicEPS | -10.90 | 3.88 | -0.52 |
| DilutedNIAvailtoComStockholders | -12.54M | 4.46M | -597.12K |
| NetIncomeCommonStockholders | -12.54M | 4.46M | -597.12K |
| NetIncome | -12.54M | 4.46M | -597.12K |
| NetIncomeIncludingNoncontrollingInterests | -12.54M | 4.46M | -597.12K |
| NetIncomeContinuousOperations | -12.54M | 4.46M | -597.12K |
| TaxProvision | 481.00 | 626.00 | |
| PretaxIncome | -12.54M | 4.46M | -596.49K |
| OtherIncomeExpense | -9.11M | ||
| OtherNonOperatingIncomeExpenses | -9.11M | ||
| NetNonOperatingInterestIncomeExpense | -342.95K | 5.80M | 0.00 |
| InterestExpenseNonOperating | 891.62K | 8.97K | 0.00 |
| InterestIncomeNonOperating | 548.68K | 5.81M | |
| OperatingIncome | -3.09M | -1.34M | -596.49K |
| OperatingExpense | 3.09M | 1.34M | 596.49K |
| ResearchAndDevelopment | 72.05K | 175.32K | |
| SellingGeneralAndAdministration | 3.09M | 1.34M | 421.18K |
| SellingAndMarketingExpense | 39.64K | 45.48K | |
| GeneralAndAdministrativeExpense | 3.09M | 1.34M | 375.69K |
| OtherGandA | 3.09M | 1.34M | 375.69K |
| GrossProfit | 0.00 | 0.00 | |
| CostOfRevenue | 0.00 | 0.00 | |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 1.15M | 1.15M | 1.15M |
| ShareIssued | 1.15M | 1.15M | 1.15M |
| NetDebt | 1.26M | 349.46K | 27.93K |
| TotalDebt | 1.27M | 360.64K | 27.97K |
| TangibleBookValue | -1.54M | -487.86K | -128.79K |
| InvestedCapital | -273.29K | -127.22K | -100.82K |
| WorkingCapital | -1.54M | -487.86K | -128.79K |
| NetTangibleAssets | -1.54M | -487.86K | -128.79K |
| CommonStockEquity | -1.54M | -487.86K | -128.79K |
| PreferredStockEquity | 32.00 | ||
| TotalCapitalization | -1.54M | -487.86K | -128.79K |
| TotalEquityGrossMinorityInterest | -1.54M | -487.86K | -128.79K |
| StockholdersEquity | -1.54M | -487.86K | -128.79K |
| RetainedEarnings | -2.78M | -1.47M | -1.11M |
| AdditionalPaidInCapital | 1.22M | 957.50K | 758.00K |
| CapitalStock | 22.03K | 22.00K | 221.50K |
| CommonStock | 22.00K | 22.00K | 221.50K |
| PreferredStock | 32.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 1.69M | 534.03K | 151.33K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 1.00 |
| OtherNonCurrentLiabilities | 3.85M | 3.85M | |
| CurrentLiabilities | 1.69M | 534.03K | 151.33K |
| OtherCurrentLiabilities | 111.03K | 626.00 | 626.00 |
| CurrentDebtAndCapitalLeaseObligation | 1.27M | 360.64K | 27.97K |
| CurrentDebt | 1.27M | 360.64K | 27.97K |
| OtherCurrentBorrowings | 1.27M | 360.64K | 27.97K |
| PayablesAndAccruedExpenses | 310.22K | 172.77K | 122.73K |
| Payables | 310.22K | 172.77K | 122.73K |
| AccountsPayable | 310.22K | 172.77K | 122.73K |
| TotalAssets | 147.99K | 46.17K | 22.54K |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 |
| GoodwillAndOtherIntangibleAssets | 4.97M | 4.90M | |
| CurrentAssets | 147.99K | 46.17K | 22.54K |
| PrepaidAssets | 144.36K | 35.00K | 22.50K |
| Receivables | 0.00 | 0.00 | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 3.63K | 11.17K | 38.00 |
| CashAndCashEquivalents | 3.63K | 11.17K | 38.00 |
| CashFinancial | 3.63K | 11.17K | 38.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| FreeCashFlow | -265.19K | 11.14K | -5.04M |
| IssuanceOfCapitalStock | 257.64K | 0.00 | 1.00M |
| CapitalExpenditure | -75.90K | -4.90M | |
| InterestPaidSupplementalData | 0.00 | 0.00 | |
| IncomeTaxPaidSupplementalData | 1.01K | 0.00 | |
| EndCashPosition | 3.63K | 11.17K | 38.00 |
| BeginningCashPosition | 11.17K | 38.00 | 185.50K |
| ChangesInCash | -7.54K | 11.14K | -185.46K |
| FinancingCashFlow | 257.64K | 0.00 | 4.85M |
| CashFlowFromContinuingFinancingActivities | 257.64K | 0.00 | 4.85M |
| NetOtherFinancingCharges | 3.85M | ||
| NetCommonStockIssuance | 257.64K | 0.00 | 1.00M |
| CommonStockIssuance | 257.64K | 0.00 | 1.00M |
| InvestingCashFlow | 0.00 | 0.00 | -4.90M |
| CashFlowFromContinuingInvestingActivities | -75.90K | -4.90M | |
| NetIntangiblesPurchaseAndSale | -75.90K | -4.90M | |
| OperatingCashFlow | -265.19K | 11.14K | -142.91K |
| CashFlowFromContinuingOperatingActivities | -265.19K | 11.14K | -142.91K |
| ChangeInWorkingCapital | 1.04M | 370.21K | 454.21K |
| ChangeInOtherCurrentLiabilities | 906.20K | 332.67K | -68.58K |
| ChangeInPayablesAndAccruedExpense | 247.85K | 50.04K | 145.29K |
| ChangeInAccruedExpense | 75.90K | 42.55K | |
| ChangeInPayable | 50.04K | 102.73K | |
| ChangeInAccountPayable | 50.04K | 102.73K | |
| ChangeInPrepaidAssets | -109.36K | -12.50K | -22.50K |
| ChangeInReceivables | 0.00 | 0.00 | 400.00K |
| DepreciationAmortizationDepletion | 0.00 | 0.00 | 0.00 |
| DepreciationAndAmortization | 0.00 | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -1.31M | -359.07K | -597.12K |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ASBP
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|